Prevalence and Clinicopathologic Risk Factors for Epidermal Growth Factor Receptor, Anaplastic Lymphoma Kinase, and ROS-1 Fusion in Metastatic Non-small Cell Lung Carcinoma

The purpose of he study was to evaluate the prevalence of epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK), and ROS-1 fusions in the patients with metastatic nonsquamous nonsmall cell lung carcinoma (NSCLC) and their relation with different demographic and clinical variables. Methods: A cross-sectional study was carried out on 87 adult patients >18 years of age with a confirmed diagnosis of Stage IV metastatic NSCLC. All the patients were studied for EGFR mutations, ALK, and ROS-1 fusions. The outcome measures were the presence of EGFR, ALK, and ROS-1 fusions among the patients with NSCLC and the risk association with age, gender, smoking, and tumor differentiation. Results: Out of 87 patients, 26 (29.89%) patients tested positive for EGFR mutations, 4 (4.6%) for ALK, and a single case for ROS-1 fusion. The mean age of the patients who were EGFR positive was significantly younger than the mean age of those without EGFR mutation (56.77 ± 12.01 vs. 66.6..... READ ARTICLE

Journal of Radiation and Cancer Research DOI:10.4103/jrcr.jrcr_43_21

Authors: Raghav Kesri, Hari Goyal, Geetanjali Gupta, Deepak Bharti and Richu Sharma

Successful treatment of de novo multiple primary malignancy with long term favorable outcome

Multiple primary malignancies have been reported in anecdotal case reports and series in literature. The de novo occurrence poses diagnostic and therapeutic challenges. The co-occurrence of lung adenocarcinoma with acute myeloid leukemia synchronously has been reported in one small series in literature. There is limited data available regarding the treatment and response outcomes in such cases, where both malignancies are molecularly and therapeutically distinct. Hence, a comprehensive workup including a complete molecular profiling is necessary to render appropriate therapy to the patient. This report elucidates the same in a case of concurrent de novo lung adenocarcinoma and acute myeloid leukemia, where complete molecular workup culminated in a successful treatment outcome. READ ARTICLE

Current Problems in Cancer: Case Reports DOI:10.1016/j.cpccr.2020.100030

Authors: Ullas Batra, Shrinidhi Nathany, Anurag Mehta, Dinesh Bhurani, Mansi Sharma, Parveen Jain, NarenderTejwani

Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India

Background: Anaplastic lymphoma kinase (ALK) rearranged metastatic non-small cell lung cancer (NSCLC) comprises 5%-7% of all lung cancer and carries a good prognosis with available ALK-inhibitors. Majority of registration trials in ALK-inhibitors did not include Indian patients. Hence, this study was planned to analyze the outcome of Indian patients treated with ALK-inhibitors and associated challenges. Results: A total of 274 patients were studied, out of which 250 patients received ALK inhibitor and were analyzed further for outcome. The median age was 50 years (range: 24-82) and male to female ratio of 1.17:1. ALK was evaluated by immunohistochemistry in majority of patients (97%), 3 patients by FISH and 3 more patients were evaluated by both methods. Sixty-five percent (n = 162) of the patients received ALK-inhibitor as first line therapy, 51 patients received ALK-inhibitor as switch maintenance therapy after initial chemotherapy. Crizotinib and Ceritinib were used in 88% and 12%,..... READ ARTICLE

Cancer DOI:10.1016/j.currproblcancer.2020.100571.

Authors: Amol Patel, Ullas Batra, Kuruswamy Thurai Prasad, Deepak Dabkara, Joydeep Ghosh, Manasi Sharma, Navneet Singh, P. Suresh, Parveen Jain, Prabhat Singh Malik, Priyanshu Choudhary, Sandip Ganguly, Sachin Khurana, Shivashankara MS, Sneha Bothra, Valliappan Muthu, Bivas Biswas,